{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:00:43Z","timestamp":1785862843537,"version":"3.56.0"},"reference-count":109,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1111\/ijcp.12771","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T09:45:05Z","timestamp":1453801505000},"page":"206-217","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Weight management in obesity \u2013 past and present"],"prefix":"10.1155","volume":"70","author":[{"given":"D.","family":"Haslam","sequence":"first","affiliation":[{"name":"The Cheyne Society Datchworth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,1,26]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"19","article-title":"The anthropomorphic figurines from Willendorf","volume":"19","author":"Antl\u2010Weiser W","year":"2008","journal-title":"Wiss Mitt Nieder\u00f6sterr Landesmuseum"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07995"},{"key":"e_1_2_6_4_1","article-title":"Midwifery and neolithic Malta: interpreting and contextualizing two terracotta figurines","author":"Rich SA","year":"2008","journal-title":"J Appl Anthropol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712221.ch1"},{"key":"e_1_2_6_6_1","unstructured":"Kingshouse.Bible Health.http:\/\/www.kingshouse.org\/Biblehealth.htm(accessed 28 October 2015)."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2015.04.003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2013.02.008"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300266"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511691843"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-004-7458-5"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3172"},{"key":"e_1_2_6_13_1","volume-title":"A Theory About sin in Relation to Some Facts of Daily Life, Lent Lectures on the 7 Deadly Sins","author":"Shipley O","year":"1875"},{"key":"e_1_2_6_14_1","volume-title":"Fat, Gluttony and Sloth. Obesity in Literature, Art and Medicine","author":"Haslam DW","year":"2009"},{"key":"e_1_2_6_15_1","unstructured":"WHO.Obesity and Overweight.http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/(accessed 27 October 2015)."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-004-7373-9"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/archinte.1983.00350120095020","article-title":"Sleep apnea. From the needles of Dionysius to continuous positive airway pressure","volume":"143","author":"Kryger MH","year":"1983","journal-title":"Arch Internal Med"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61065-3"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00608.x"},{"key":"e_1_2_6_20_1","unstructured":"Museum of the Royal Pharmaceutical Society.Developing Treatments: Obesity 2009.http:\/\/www.rpharms.com\/museum-pdfs\/obesity.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_21_1","unstructured":"HaslamD.The Weight of Obsession. A Brief but Wide History 2015.https:\/\/commonreader.wustl.edu\/c\/the-weight-of-obsession(accessed 28 October 2015)."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1933.02740280013006"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.24.10.1045"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113482532"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-5-200509060-00013"},{"key":"e_1_2_6_26_1","first-page":"117","article-title":"Preludin (phenmetrazine) in the treatment of obesity","volume":"76","author":"Martel A","year":"1957","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(77)71101-6"},{"key":"e_1_2_6_28_1","first-page":"29","article-title":"Study of phendimetrazine bitartrate as an appetite suppressant in relation to dosage, weight loss and side effects","volume":"87","author":"Riche WH","year":"1962","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.110593"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:29:1:49"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.74"},{"key":"e_1_2_6_32_1","unstructured":"Drug Amendments of 1962. Pub L No. 87\u2010781 76 Stat 780 1962.http:\/\/www.gpo.gov\/fdsys\/pkg\/STATUTE-76\/pdf\/STATUTE-76-Pg780.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_33_1","volume-title":"The Code of Federal Regulations of the United States of America: 201.200 Disclosures of Drug Efficacy Study Evaluations in Labeling and Advertising","author":"United States Food and Drug Administration","year":"1999"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.69"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.76"},{"key":"e_1_2_6_36_1","unstructured":"United States Food and Drug Administration.Guidance for the Clinical Evaluation of Weight\u2010Control Drugs 1996.http:\/\/www.fda.gov\/ohrms\/dockets\/98fr\/03d-0570-gdl0001.pdf. Superseded by 2007 guidance.http:\/\/www.fda.gov\/downloads\/Drugs\/%e2%80%a6\/Guidances\/ucm071612.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_37_1","unstructured":"EEC Council Regulations.Council Regulation (EEC) No 2309\/93 of 22 July 1993 Laying Down Community Procedures for the Authorization and Supervision of Medicinal Products for Human and Veterinary use and Establishing a European Agency for the Evaluation of Medicinal Products 1993.http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/reg_1993_2309\/reg_1993_2309_bg.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-3565(25)38720-3","article-title":"Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated","volume":"269","author":"McCann U","year":"1994","journal-title":"Pharmacol Exp Ther"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00289-8"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_6_41_1","article-title":"Fen\u2010Phen Maker to Pay Billions In Settlement of Diet\u2010Injury Cases","author":"Morrow DJ","year":"1999","journal-title":"The New York Times"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801889"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2006.47.5.614"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01242.x"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850222"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108095195"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015912799362788"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39385.413113.25"},{"key":"e_1_2_6_49_1","unstructured":"BeastonP.BPCA Executive Summary: Clinical Review for New Drug Application 20\u2010632 SE5\u2010021 2005.http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM163209.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sui086"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_2_6_52_1","unstructured":"United States Food and Drug Administration.Meridia (Sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events 2010.http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm228830.htm(accessed 28 October 2015)."},{"key":"e_1_2_6_53_1","unstructured":"European Medicines Agency.Questions and Answers on the Suspension of Medicines Containing Sibutramine 2010.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Sibutramine_107\/WC500094238.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01554.x"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2013.11.1.7"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1936"},{"key":"e_1_2_6_58_1","unstructured":"Roche.Xenical Summary of Product Characteristics 2013.http:\/\/www.medicines.org.uk\/emc\/document.aspx?documentid=1746(accessed 28 October 2015)."},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1529"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61721-8"},{"key":"e_1_2_6_61_1","unstructured":"United States Food and Drug Administration.Briefing Document NDA 21\u2010888 Zimulti (Rimonabant) Tablets 20 mg 2007.http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4306b1-fda-backgrounder.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_62_1","unstructured":"European Medicines Agency.The European Medicines Agency Recommends Suspension of the Marketing Authorisation of Acomplia 2009.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2009\/11\/news_detail_000244.jsp(accessed 28 October 2015)."},{"key":"e_1_2_6_63_1","unstructured":"Drugs.com. Accomplia.http:\/\/www.drugs.com\/acomplia.html(accessed 28 October 2015)."},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.103"},{"key":"e_1_2_6_65_1","unstructured":"United States Food and Drug Administration.Lorcaserin Briefing Information: Endocrinologic and Metabolic Drugs Advisory Committee 2012.http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/ucm225628.htm(accessed 28 October 2015)."},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.112.000128"},{"key":"e_1_2_6_68_1","unstructured":"United States Food and Drug Administration.FDA Approves Belviq to Treat Some Overweight or Obese Adults 2012.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm309993.htm(accessed 28 October 2015)."},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1256"},{"key":"e_1_2_6_70_1","unstructured":"Arena Pharmaceuticals.Lorcaserin for Obesity Passes Major Safety Milestone. Month\u201012 Independent Echocardiographic Data Safety Monitoring Board Review Strengthens Lorcaserin's Emerging Cardiovascular Safety Profile 2008.http:\/\/invest.arenapharm.com\/common\/mobile\/iphone\/releasedetail.cfm?ReleaseID&320197%26CompanyID=ARNA(accessed 28 October 2015)."},{"key":"e_1_2_6_71_1","unstructured":"European Medicines Agency.Withdrawal of the Marketing Authorisation Application for Belviq (Lorcaserin) 2013.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2013\/05\/WC500143811.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.790957"},{"key":"e_1_2_6_73_1","unstructured":"Unites States Food and Drug Administration.FDA Approves Weight\u2010Management Drug Qsymia 2012.www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm312468.htm(accessed 28 October 2015)."},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20584"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1211277"},{"key":"e_1_2_6_79_1","unstructured":"European Medicines Agency.Refusal of the Marketing Authorisation for Qsiva (Phentermine\/Topiramate) 2012.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002350\/WC500134085.pdf(assessed 28 October 2015)."},{"key":"e_1_2_6_80_1","unstructured":"EUDRACT.A Qsymia\u2122CardiovascuLAr MorbIdity and Mortality (AQCLAIM) Study in Subjects With Documented Cardiovascular Disease.http:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=AQCLAIM(accessed 28 October 2015)."},{"key":"e_1_2_6_81_1","unstructured":"Unites States Food and Drug Administration.Contrave (Naltrexone 4 mg 8 mg\/Bupropion HCL 90 mg Extended Release Tablet) Briefing Document NDA 200063 2010.http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicandmetabolicdrugsadvisorycommittee\/ucm235671.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_82_1","unstructured":"United States Food and Drug Administration.Center for Drug Evaluation and Research. Application Number 200063Orig1s000. Summary Review 2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/200063Orig1s000SumR.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_2_6_84_1","unstructured":"GuettierJ\u2010MP.Contrave NDA Approval Letter 2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/200063Orig1s000ltr.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_85_1","unstructured":"Cleveland Clinic.Clinical Trial Testing Safety of Obesity Drug Contrave Halted; 50 Percent Interim Data Released by the Study's Executive Committee.http:\/\/my.clevelandclinic.org\/about-cleveland-clinic\/newsroom\/releases-videos-newsletters\/2015-5-12-clinical-trial-testing-safety-of-obesity-drug-contrave-halted(accessed 28 October 2015)."},{"key":"e_1_2_6_86_1","unstructured":"European Medicines Agency.Mysimba Summary of Product Characteristics.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003687\/WC500185580.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_87_1","unstructured":"European Medicines Agency.Victoza Summary of Product Characteristics.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001026\/WC500050017.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1355"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61246-5"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2124"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1472-y"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60307-8"},{"key":"e_1_2_6_95_1","unstructured":"United States Food and Drug Administration.Highlights of Prescribing Information for Victoza\u00ae(Liraglutide Injection).http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/022341s023lbl.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/379069a0"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_6_99_1","unstructured":"SmithJP.Saxenda NDA Approval Letter 2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2014\/206321Orig1s000ltr.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_100_1","unstructured":"European Medicines Agency.Saxenda Summary of Product Characteristics 2015.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003780\/WC500185786.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_101_1","unstructured":"United States Food and Drug Administration.FDA Approves Weight\u2010Management Drug Saxenda 2014.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm427913.htm(accessed 28 October 2015)."},{"key":"e_1_2_6_102_1","unstructured":"European Medicines Agency.Assessment Report: Saxenda 2015.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003780\/WC500185788.pdf(accessed 28 October 2015)."},{"key":"e_1_2_6_103_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1076699"},{"key":"e_1_2_6_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803446"},{"key":"e_1_2_6_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.155"},{"key":"e_1_2_6_106_1","unstructured":"Takeda.Norgine and Takeda Announce the New Drug Application Approval of OBLEAN\u00aeTablets 120 mg in Japan for the Treatment of Obesity With Complications 2013.http:\/\/www.takeda.com\/news\/2013\/20130920_5991.html(accessed 28 October 2015)."},{"key":"e_1_2_6_107_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0809"},{"key":"e_1_2_6_108_1","unstructured":"Orexigen.Orexigen\u00aeTherapeutics Phase 2b Trial for Empatic\u2122Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus Comparators in Obese Patients 2015.http:\/\/ir.orexigen.com\/phoenix.zhtml?c&207034%26p=irol-newsArticle%26ID=1336796(accessed 28 October 2015)."},{"key":"e_1_2_6_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12457"},{"key":"e_1_2_6_110_1","unstructured":"An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02324491(accessed 28 October 2015)."}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12771","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijcp.12771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijcp.12771","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijcp.12771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T07:04:14Z","timestamp":1748761454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,26]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/ijcp.12771"],"URL":"https:\/\/doi.org\/10.1111\/ijcp.12771","archive":["Portico"],"relation":{},"ISSN":["1368-5031","1742-1241"],"issn-type":[{"value":"1368-5031","type":"print"},{"value":"1742-1241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,26]]}}}